InSysBio announces its participation in An Introduction to QSP, A UK QSP Network hybrid (in person/online) event which is to be held 17-20hrs 24th October 2024. Oleg Demin Jr, Scientific Director, Oncology & Immuno-Oncology, will discuss the prediction of the first-in-human dose for T-cell engagers using mechanistic modelling.
October 24, 18.15-18.50
Oleg Demin Jr comments on the topic, "While the minimal anticipated biological effect level (MABEL) PK-driven approach is recommended for determining the safe clinical starting dose for T-cell engagers (TCE), this method can sometimes yield a low minimal recommended starting dose (MRSD) resulting in treatment of patients with sub-therapeutic doses and multiple dose escalations. Quantitative Systems Pharmacology (QSP) modeling is another approach to predict MRSD for TCE with potentially higher predictive power. In my presentation, I will discuss the advantages and challenges of mechanistic modeling for the selection of MRSD and compare it with the MABEL PK-driven approach using a case study on HPN536, a TCE targeting mesothelin."
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
← | March 2018 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
|
4
| |||
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
1.
12 Mar 2018 14:19
InSysBio to present at AAT-AD/PD Focus Meeting 2018
InSysBio today announced their participation at AAT-AD/PD Focus Meeting 2018, to be held in Torino, Italy, on March 15-18, 2018. The Meeting is focused on all the latest breakthroughs in treatment and research in Alzheimer’s, Parkinson’s and other neurological diseases. Alexander Stepanov will present “In silico implementation of tauopathy transgenic mouse model” in the framework of session “Symposium 25: Tau in translational studies (2)”.
|
13
|
14
|
15
1.
15 Mar 2018 15:43
InSysBio to present at the ASCPT 2018 Annual Meeting
InSysBio today announced their participation at the ASCPT 2018 Annual Meeting, to be held in Orlando, FL, on March 21-24.
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
|
31
|